Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is the mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a percutaneous coronary intervention (PCI) or are managed medically. In recent years, the most appropriate timing for initiation and duration of P2Y 12 receptor inhibition has been a focus of great interest. Many observational studies and a single prospective trial (CREDO) utilizing clopidogrel had focused on whether pre-treatment with clopidogrel, i.e. its administration upstream of coronary angiography and PCI, is beneficial. Although the rationale for pre-treatment is obvious, large-scale randomized trials supporting a pretreatment strategy with clopidogrel or with the newer P2Y 12 inhibitors prasugrel and ticagrelor did not exist. Proponents of a pre-treatment strategy had to rely on their best guess, on non-randomized studies, or on negative studies in which a trend for a benefit had been demonstrated. Recently, however, two randomized trials directly evaluated the value of pre-treatment-one in patients with a non-STE elevation myocardial infarction ( And given the recent approval of the intravenous and rapidly acting P2Y 12 inhibitor cangrelor, the choice of who should receive treatment with a P2Y 12 inhibitor, which one should be used, and when it should be administered, should be carefully re-evaluated for all patients. This clinical review aims at evaluating the available evidence regarding the value of pre-treatment with the now four available oral and intravenous P2Y 12 inhibitors that can be administered to patients in whom coronary angiography followed by a possible PCI is planned.
Introduction
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is the current mainstay of pharmacological treatment in acute coronary syndrome (ACS) patients managed non-invasively or invasively by percutaneous coronary intervention (PCI). 1 -5 The goal of DAPT is to reduce the risk of ischaemic events such as (re)-infarction and, in patients in whom a PCI is performed, the risk of stent thrombosis. It is logical to assume that early administration of a P2Y 12 inhibitor prior to coronary angiography (referred to as upstream therapy, or pre-treatment) and PCI should provide greater benefit given the fact that even the fastest acting oral P2Y 12 inhibitors take at least 30 -60 min under stable conditions (and even longer in a STEMI setting) 6 to achieve maximal platelet inhibition, by which time most PCI procedures have already been completed. However, the downside of inhibiting platelets prior to an invasive procedure includes increasing the risk of bleeding. 7 -9 In line with the belief that platelets are key mediators of both ischaemic coronary events and primary haemostasis, it has been shown that the level of platelet inhibition achieved at the time of the intervention (PCI) correlates with both thrombotic and bleeding events. 10 Moreover, some patients undergoing coronary angiography will be found to require coronary artery bypass surgery (CABG); the risk of operating on such patients before the P2Y 12 inhibitor has worn off has been clearly demonstrated and should be avoided whenever possible. Delaying surgery until the drugs' antiplatelet effects have worn off also has risks, and is expensive in case it requires prolonging a hospitalization. During the last decade, numerous observational studies, randomized trials, 11, 12 and meta-analyses 13, 14 have provided conflicting results on the value of pre-treatment with the most commonly used P2Y 12 inhibitor, namely clopidogrel. This drug has only moderate strength at inhibiting platelet aggregation and more potent antiplatelet agents like prasugrel or ticagrelor would be expected to be more likely to increase the efficacy of pre-treatment, and to increase bleeding complications as well. Due to the lack of clear evidence favouring pre-treatment for stable coronary artery disease (CAD) patients, current guidelines do not recommend routine pretreatment in this cohort [class III, level of evidence (LOE) A] 15 or state that it may be considered in patients with high likelihood of significant CAD (class IIb, LOE B). 1 Since the underlying pathophysiology for ACS patients differs in that blood platelets are more highly activated, and ruptured plaques with thrombus are generally present in at least one coronary artery, 16 pre-treatment in ACS patients is biologically appealing and intuitively more likely to be beneficial in this specific group of patients. Accordingly, the potent antiplatelet agents prasugrel and ticagrelor have been studied in dedicated trials comparing pre-treatment vs. no pretreatment with the same agents. 7, 17 Randomized studies of pretreatment with prasugrel are available for NSTEMI patients only; in contrast, pre-treatment with ticagrelor was only studied in STEMI patients. Further on, recent trials 18 -20 have provided some information about the benefit of pre-treatment with the first available intravenous agent cangrelor, a novel drug expanding treatment options upstream or during PCI. This review aims to evaluate the available evidence regarding the value of pre-treatment with available oral and intravenous P2Y 12 inhibitors that can be administered to patients in whom coronary angiography and possible PCI is planned.
Pre-treatment with P2Y 12 receptor antagonists in acute coronary syndrome
Blood platelets are highly activated in the acute phase of an ACS. 16 This forms the basis of why it is believed that potent platelet inhibition is needed in ACS patients. This is especially true for patients undergoing PCI, which itself activates platelets. The platelet G-protein-coupled P2Y 12 receptor amplifies and maintains in vivo platelet activation in response to adenosine diphosphate (ADP). Targeting this receptor with antiplatelet drugs can be accomplished with monotherapy with just a P2Y 12 inhibitor, but in the setting of an ACS, dual antiplatelet therapy consisting of aspirin and a P2Y 12 receptor inhibitor was found to be superior to monotherapy and is common clinical practice, whether or not a PCI is planned.
1 Figure 1 illustrates the rationale behind pre-treatment prior to angiography and a possible PCI. Pre-treatment aims at achieving a maximal level of inhibition of platelet aggregation at the time of PCI in the hope of reducing periprocedural infarctions, as well as stent thrombosis during and early after the procedure when the risk is greatest. The logic behind such a strategy of potent and immediate platelet inhibition is clear and has built the rationale for different randomized controlled trials. 7 -9,17 All those appealing strategies have pros and cons 21 -23 and Figure 2 highlights the potential benefits and disadvantages of pre-treatment in a scenario of coronary angiography with possible PCI. The term 'pre-treatment' defines a strategy according to which an antiplatelet drug, usually a P2Y 12 inhibitor, is given before coronary angiography is performed. Thus, administration of a P2Y 12 inhibitor in the ambulance (pre-hospital setting), 17 in the emergency department, coronary care unit, or even in the catheterization laboratory before coronary angiography is performed can all be appropriately considered to represent pre-treatment. Importantly, the term pretreatment should not be used for administration of P2Y 12 inhibitors immediately before a PCI. In principle, all available P2Y 12 receptor inhibitors can be used for pre-treatment in ACS patients. However, administering a P2Y 12 inhibitor only shortly before a PCI, before its antiplatelet effects become manifest, is unlikely to be optimal; hence the term 'adequate pre-treatment', referring to pre-treatment with a sufficient time before the procedure for the P2Y 12 inhibitor to achieve maximal inhibition of platelet aggregation. Table 1 provides a summary of the four available P2Y 12 inhibitors (three oral and one intravenous agent), their pharmacological properties, 24 and key characteristics. Table 2 summarizes selected studies on pretreatment with currently available P2Y 12 inhibitors. For each agent, the available study data on pre-treatment will be summarized and discussed below.
Clopidogrel
Clopidogrel, an orally administered P2Y 12 receptor inhibitor with an irreversible mode of action, received approval in 1997 following the CAPRIE trial, a randomized comparison of clopidogrel alone vs. aspirin alone in patients with atherosclerotic vascular disease. 25 This second-generation thienopyridine is an inactive pro-drug that requires two-step oxidation by the hepatic cytochrome P450 (CYP) system to generate its active compound, the thiol metabolite, which targets and irreversibly inhibits ADP P2Y 12 receptor on blood platelets. 26, 27 Because clopidogrel is a pro-drug that requires in vivo bioactivation, drug response is highly variable due to differences in both the degree to which patients can absorb and metabolize the drug and also due to well-characterized drug -drug interactions on a pharmacodynamic level (proton pump inhibitors, e.g. omeprazole). Some patients have persistent high on-treatment platelet reactivity despite taking a P2Y 12 inhibitor with sufficient time in advance of a PCI, which itself is associated with mortality risk and a higher risk of ischaemic events including early stent thrombosis. 28 Importantly, clopidogrel is also characterized by a slow onset of action: maximum levels of platelet inhibition are not achieved until at least 2 h after administration of a loading dose of 600 mg, which represents eight times the 75 mg maintenance dose of the drug. 29 The relatively slow onset of action of clopidogrel has motivated the interest in pre-treatment strategies with the drug, 30, 31 since if 600 mg of clopidogrel is given to a patient after a diagnostic coronary angiogram and immediately before a PCI, little inhibition will be manifest by the time most PCI procedures are completed. Interestingly, initial studies of clopidogrel pre-treatment go back to the era of fibrinolytic therapy. In PCI-CLARITY, 32 a pre-specified who are at greatest risk of bleeding, were excluded from the trial. In addition, only 300 mg of clopidogrel was administered. Benefit from pre-treatment with clopidogrel was also suggested by PCI-CURE, 12 a pre-specified but post-randomization sub-group analysis of the CURE trial. 34 In PCI-CURE, the primary study endpoint [a Figure 1 The course of the level of platelet inhibition over time in patients with P2Y 12 pre-treatment (green curve) and in patients without pre-treatment (red curve). The opportunity to benefit from pre-treatment effect exists within the area with slanted grey lines, the area between the red and green curves. The risk of stent thrombosis (black curve) is highest during and in the early period after percutaneous coronary intervention with a subsequent decline in ST risk thereafter. Following a loading dose with P2Y 12 inhibitors, the maximum level of platelet inhibition is usually seen within hours and up to the day after percutaneous coronary intervention, with a minor decline in inhibition during maintenance therapy before reaching a steady-state level.
48 Figure 2 The potential benefits and disadvantages of P2Y 12 pre-treatment in patients undergoing percutaneous coronary intervention. CABG, coronary artery bypass grafting. PCI, percutaneous coronary intervention. was designed with two co-primary endpoints to both evaluate the benefit of initiating pre-treatment with clopidogrel 3 -24 h before PCI, and, of continuing clopidogrel for 12 months vs. 1 month after the procedure. However, a 300 mg loading dose was utilized in the pre-treatment arm, which is not only much slower than a 600 mg loading dose but also leads to lesser inhibition of aggregation than a 600 mg loading dose. 31 In CREDO, pre-treatment was associated with an 18% relative risk reduction in the primary endpoint of death, MI, or urgent target-vessel revascularization at 28 days, but the difference did not come close to being statistically significant (P ¼ 0.23). A significant interaction (P int ¼ 0.02) was found between the duration of pre-treatment and a reduction in the primary endpoint. In a pre-specified sub-group analysis, the benefit of pretreatment appeared to be most likely amongst patients who received clopidogrel at least 6 h before their PCI [a 38.6% reduction (95% CI, 21.6 -62.9%); P ¼ 0.051]. Balancing the potential benefit from pre-treatment was the observed trend towards more major bleeding in the pre-treatment arm (8.8% with clopidogrel vs. 6.7% with placebo at one year; P ¼ 0.07). Despite the limitations of CRE-DO, many believe that the trial lends at least some support to a pretreatment strategy.
Numerous observational studies and smaller randomized trials (see also (including a lytic trial) with different combined endpoints and different endpoint definitions. Thus, such analyses are important but cannot be considered definitive; rather, they should be considered hypothesis generating, or suggestive. Indirect evidence in favour of pre-treatment with clopidogrel can be derived from several ISAR-REACT trials. Pre-treatment with a high loading dose (LD; 600 mg) of clopidogrel, recommended to be given at least 2 h before the procedure, was standard of care in most of the ISAR studies. However, pre-treatment was not randomized in any of these studies. Glycoprotein IIb/IIIa inhibitors (GPIs) did not reduce the risk of thrombotic events in biomarkernegative ACS patients undergoing PCI (ISAR-REACT 2), 35 12 receptor inhibitors. It also shows the average onset of action for the P2Y12 inhibitors. The onset of action is significantly delayed in STEMI and cardiogenic shock patients for all oral P2Y12 inhibitors. 6 Following intestinal absorption, ticagrelor does not need to be metabolized to inhibit platelet aggregation. However, a metabolite (AR-C124910XX) is also active (*). Pricing are treatment costs per day (source: www.rote-liste.de) for the oral agents (generic drug price for clopidogrel) and price per vial for cangrelor. LD, loading dose; MD, maintenance dose.
P2Y 12 pre-treatment in ACS ACS patients in whom PCI was planned following the results of the TRITON-TIMI 34 trial. 8 In 13 608 ACS patients (including patients with unstable angina, NSTEMI, and STEMI), prasugrel reduced the risk of ischaemic events compared with clopidogrel when given immediately before the PCI procedure [9.9 vs. 12.1%, Hazard ratio (HR) 0.81, 95% CI 0.73 -0.90 for the primary combined ischaemic study endpoint]. The benefit from 'pre-treatment' with prasugrel immediately before PCI was associated, however, with a significantly higher risk of major bleeding observed at the end of the study period (2.4 vs. 1.8%, HR 1.32, 95% CI 1.03-1.68). However, the claims regarding the apparent benefit from pre-treatment in TRITON-TIMI are weakened for the following two reasons: first, patients in TRI-TON (except for STEMI patients and the few patients with known coronary anatomy) could not receive their assigned treatment (prasugrel or clopidogrel) until after coronary angiography, immediately before the PCI (and even most STEMI patients received study drug at that time). Second, only 300 mg of clopidogrel was administered in the clopidogrel arm, rather than 600 mg, the dose already preferred in clinical practice at the time the study was performed, which is not only more rapidly acting but also slightly stronger when assessed by ex vivo inhibition of aggregation. 31 Thus, the study provides no evidence about an 'adequate pre-treatment' (pre-treatment for a sufficient time before PCI for the P2Y12 inhibitors to achieve maximal inhibition of aggregation) with prasugrel vs. a 600 mg loading dose of clopidogrel. Subsequently, the ACCOAST trial 7 (see also Tables 2 and 3) was specifically designed to assess the value of pre-treatment with prasugrel in NSTEMI patients in whom PCI was planned. In that study, biomarker-positive ACS patients in whom an early invasive strategy was planned (within 48 h) were randomized to receive either 30 mg prasugrel before diagnostic angiography followed by 30 mg prasugrel at the time of PCI (pre-treatment group) or placebo before angiography, followed by the full dose of 60 mg prasugrel after diagnostic angiography and before PCI (control group with which the primary efficacy endpoint was reached (a composite of cardiovascular death, MI, stroke, urgent revascularization, or unplanned use of GPIs through 7 days) did not differ between the two study groups (10.0 vs. 9.8%, HR 1.02, 95% CI, 0.84-1.25). Furthermore, patients in the pre-treatment group had a near doubling of major bleeding complications (2.6 vs. 1.4%; HR 1.90, 95% CI 1.19-3.02 for TIMI major bleeding), ultimately leading to premature termination of the trial based on a recommendation by the Data Safety Monitoring Board. Despite the early termination, 398 of the 400 intended primary endpoints had been collected by the time the study was halted, after 4033 of 4100 planned patients had been enrolled. Thus, the trial is robust enough to indicate that routine pre-treatment with prasugrel in an NSTEMI cohort is not beneficial but even harmful, compared with the administration of prasugrel immediately before a PCI procedure, and ought not to be performed. In a subsequent post hoc analysis of ACCOAST, the two strongest independent predictors for TIMI major bleeding were pre-treatment with prasugrel (HR 3.02; 95% CI 1.42 -6.43), followed by femoral access for PCI (HR 2.45; 95% CI 1.11 -5.38).
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Sub-group analyses could not identify any group for whom pretreatment was beneficial, with the possible exception of patients with a short delay (less than the median delay of approximately 15 h) between symptom onset and the administration of prasugrel; in such patients, a suggestion of benefit from pre-treatment was observed (with an interaction value of P int ¼ 0.004 compared with patients receiving pre-treatment with prasugrel greater than the median duration of time from symptom onset to pre-treatment). This finding should be considered hypothesis generating only. A small pharmacodynamic sub-study revealed a closing of the gap of both study arms and similar levels of inhibition of platelet aggregation 2 h after PCI and after administration of the second loading dose and placebo dose in the two arms. This suggests that the relatively small amount of time between the cumulative administrations of a full 60 mg loading dose in the two treatment arms might partially explain, or at least contribute to, the lack of benefit from pre-treatment in the study. Nonetheless, the time difference was sufficient to produce twice as much major bleedings in the pretreatment arm. It has been debated whether these data reflect the value of pre-treatment in general, or ought to only be relevant to pre-treatment with prasugrel. there is lack of data on the value of prasugrel pre-treatment in STE-MI patients specifically. In this respect, head-to-head comparisons for prasugrel vs. ticagrelor including pre-treatment strategies in NSTEMI and STEMI patients would be important. While only smaller randomized or observational studies ( 
Ticagrelor
Ticagrelor is an orally administered P2Y 12 inhibitor very different from the other oral P2Y 12 inhibitors available. In that ticagrelor is direct acting it does not need to be metabolized to provide its effect on platelets (although the main metabolite resulting from the metabolism of ticagrelor is also pharmacologically active). Ticagrelor has a reversible mode of action ( Table 1 ). The drug received approval for treatment of ACS patients based on the PLATO trial. 9 In PLATO, 18 624 patients suffering an NSTEMI or STEMI, regardless of whether an invasive (PCI or CABG) or non-invasive strategy was planned, were randomized to immediately receive ticagrelor or clopidogrel (with a 300 -600 mg loading dose) upstream of any cath lab procedures that might take place later. Therefore, PLATO was not a trial of pre-treatment vs. no pre-treatment; patients in both arms received their P2Y 12 inhibitors before any invasive procedures that were ultimately performed. Ticagrelor reduced the risk of ischaemic events (9.8 vs. 11.7%, HR 0.84, 95% CI 0.77 -0.92 for the primary study endpoint of death from vascular cause, MI or stroke). No significant differences in the frequency of major bleeding (related to CABG or not) were observed, according to PLATO bleeding criteria (11.6 vs. 11.2%, HR 1.04, 95% CI 0.95-1.13). However, the frequency of non-CABG-related bleeding was higher with ticagrelor (4.5 vs. 3.8%, HR 1.19, 95% CI 1.02-1.38). While the trial was not specifically designed to evaluate a pre-treatment strategy, PCI patients in PLATO received the study drug before the PCI procedure and the duration of time from study drug to the procedure was a median of 0.25 h in STEMI patients and 3.6 -3.9 h in NSTEMI patients. Thus, the sub-group of patients in PLATO who did ultimately undergo PCI was pre-treated with ticagrelor vs. clopidogrel. Accordingly, based on PLATO, current guidelines 1 recommend ticagrelor 'for patients at moderate-to-high risk of ischaemic events, regardless of the initial treatment strategy and including those pretreated with clopidogrel if no contraindication' (class I, LOE B). The value of pre-treatment with ticagrelor was directly addressed in the Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST-Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial 17 ( Table 3 ). The ATLANTIC trial was designed specifically to compare pre-hospital pre-treatment with ticagrelor (in either the ambulance or emergency department, where ever the patient first encountered an enrolling provider) with cath lab administration of ticagrelor exclusively in patients suffering a STEMI in whom primary PCI was planned. Since only 1862 patients were enrolled, ATLANTIC was not powered to be able to identify the superiority of pre-treatment with respect to hard clinical endpoints; therefore, two surrogate endpoints were used instead as the co-primary outcome measures: the absence of ≥70% resolution of ST-segment elevation assessed just prior to PCI, and, the frequency of less than TIMI III flow in the infarct-related artery on the initial coronary angiogram. No significant differences were observed in either endpoint (absence of ≥70% resolution of ST-segment elevation 86.8 vs. 87.6%, respectively, P ¼ NS; absence of TIMI III flow, 82.6 vs. 83.1%, respectively, also P ¼ NS). While there was no significant interaction with age, gender, diabetes, or use of other antiplatelet agents, the authors observed a highly significant interaction with morphine use (P int ¼ 0.005); a significant benefit appeared to have been derived from pre-treatment when no morphine was used, by physician preference, in the treatment of chest discomfort. The investigators speculated that pre-hospital morphine use might have attenuated the potential benefits of upstream ticagrelor; this finding ought to be viewed as hypothesis generating only. Further studies are needed here and the ongoing phase IV Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION) study is exploring the pharmacodynamic effects of morphine on ticagrelor absorption and its antiplatelet action. 41 A secondary clinical endpoint, the frequency of definite stent thrombosis at 30 days, was significantly reduced by pre-treatment, although the degree of benefit (reduction in stent thrombosis rate) was so great ([11 events (1.2%) for the in-hospital ticagrelor group vs. two events (0.2%) for the pre-hospital group, OR 0.19, 95% CI 0.04 -0.86, P ¼ 0.02]) that it is almost certain that at least some chance was involved in this finding. The reduction in stent thrombosis was not accompanied by a strong trend, or in fact any trend, in a reduction in the combined ischaemic secondary endpoint of death, MI, stent thrombosis, stroke, and urgent revascularization, which was similar between the pre-treatment and non-pretreatment group (4.5 vs. 4.4%, OR 1.03, 95% CI 0.66 -1.60, P ¼ 0.91). In fact, numerically higher mortality rates at 30 days were found in the pre-treatment group of patients (3.3 vs. 2.0%, OR 1.68, 95% CI 0.94-3.01, P ¼ 0.08). Thus, there was a surprising disconnect between stent thrombosis and mortality in ATLANTIC. 17 Interestingly, this surprising finding was also found in the DAPT trial, 42 in which a longer duration of DAPT reduced stent thrombosis but increased mortality. Both findings remain unexplained and warrant further investigations. While a positive secondary endpoint (stent thrombosis) in a trial that did not reach its primary endpoint (or in this case, either primary endpoints) or even produce a reduction in any other important clinical endpoint, ought not to be viewed as strong evidence (and in fact, some argue that it provides no evidence in support of pre-treatment at all), it is intuitive that patients who receive a drug earlier will be protected from thrombotic complications earlier. Clinicians who advance this argument also note that the two more feared adverse effects from pre-treatment, procedural bleeding, and the need to delay emergency CABG, were not found in the ATLANTIC trial. The frequency with which CABG is required in STEMI patients is quite low (much less than 5% in most recently STEMI trials, and ,2% in ATLANTIC). Furthermore, the risk of procedural bleeding is significantly reduced when radial artery access is used to perform the procedure (and was employed in 67% of patients in ATLANTIC). So, although ATLANTIC must be considered a negative trial, some clinicians interpret the trial as weakly supportive of pre-treatment in patients in whom a definite STEMI is present, particularly when radial artery access is planned. It may well be that the very short difference in time between the administration of ticagrelor in the two arms (31 min) makes it very difficult for pre-treatment to have been superior to in-lab treatment; conceptually, pre-treatment would be expected to be of greater benefit (if it is beneficial at all) when a greater duration of pretreatment is achieved. Moreover, we may have to question the principle role of P2Y12 inhibitors as reperfusion supporting agents in STEMI patients. Thus, surrogate endpoints like TIMI flow and ST-segment elevation resolution, reflecting coronary reperfusion, might simply miss the effect of any early P2Y12 inhibitor treatment in this cohort of patients. However, a combined clinical endpoint (secondary study endpoint) did not show any differences between the two treatment arms as well. Lastly, it should be remembered that 10% of patients in ATLANTIC did not receive revascularization by either PCI or CABG, 17 which was in part related to an incorrect pre-hospital diagnosis of STEMI. Since some patients with chest discomfort consistent with infarction will be instead found to have aortic dissection, a highly morbid condition requiring emergent surgery, it is clear that pre-treatment with ticagrelor (or any oral P2Y 12 inhibitor) ought to be avoided in patients in whom the presence of an ACS is uncertain and aortic dissection may be present. While it is possible to start prasugrel or ticagrelor pre-treatment in the ambulance if the diagnosis of STEMI is confirmed, current data do not favour this over the in-lab administration of the drug. Either strategy can be employed based on the available data, which is consistent with the wording in the current guidelines.
Cangrelor
Cangrelor is the first intravenous and competitive P2Y 12 inhibitor, with a reversible mode of action and a very short half-life of ,5 min. Cangrelor belongs to a new family of drugs termed as ATP analogues. The rapid onset is made possible by its being direct acting on the P2Y 12 receptor, without the need for in vivo bioactivation ( Table 1) . Cangrelor has been investigated in three large-scale phase III randomized clinical trials within the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) Programme. 18 -20 While the value of pre-treatment was not directly investigated within this series of trials, in all three trials, the cangrelor arm provided earlier P2Y 12 inhibition than the control arm. In all three CHAMPION trials, 18 -20 cangrelor initiated immediately before the PCI followed by a transition to clopidogrel was compared with a clopidogrel-only treatment strategy, most often administered following the PCI. Both the CHAMPION-PCI 20 and CHAMPION-Platform 18 trials were negative-they failed to show a reduction in periprocedural complications in the 48 h after the PCI procedure, the primary endpoint of all 3 trials. The third CHAMPION trial, CHAMPION-PHOENIX, 19 however, differed in that it utilized the third universal definition of periprocedural MI, 43 which had not been part of the prior CHAMPION studies. Perhaps as a result of the far more sensitive definition of procedural MI, the CHAMPION-PHOENIX investigators were able to show a significant reduction in the primary composite ischaemic endpoint of death, MI, ischaemiadriven revascularization, or stent thrombosis at 48 hours (4.7 vs.
5.9%, OR 0.78, 95% CI 0.66-0.93, P ¼ 0.005) in the cangrelor arm of the study, primarily driven by a reduction in periprocedural MI (3.8 vs. 4.7%, P ¼ 0.02) and stent thrombosis at 48 h (0.8 vs. 1.4%, P ¼ 0.01). Approximately one-fourth of patients assigned to clopidogrel only received a 300-mg loading dose, and 37% of patients in the clopidogrel group received the study drug during or after, rather than before, their PCI. No information of the duration of time between receipt of study drug and the PCI are provided for the 63% of the patients who received clopidogrel before the procedure. And no patients received the more rapidly acting P2Y 12 inhibitors prasugrel and ticagrelor. The primary bleeding endpoint of GUSTO severe or life-threatening bleeding, a vastly less sensitive endpoint than that was used in other P2Y 12 inhibitor trials, was infrequently reached and did not differ between the two study arms (0.16 vs. 0.11%, OR 1.50, 95% CI 0.53 -4.22, P ¼ 0.44). In a meta-analysis of the first two negative CHAMPION trials (CHAMPION-PCI and CHAMPION-PLATFORM) and the third, positive CHAMPION-PHOENIX trial 44 using patient-level data, a modified intention-to-treat population (n ¼ 24 910 patients) was analysed. Key findings included that cangrelor, when compared with therapy in the control arms (clopidogrel or placebo), reduced the combined frequency of death, MI, ischaemiadriven revascularization, or stent thrombosis at the expense of an increased bleeding risk, which was mostly bleeding that did not qualify as major using the GUSTO bleeding scale. Although the CHAMPION trials were not specifically designed to assess the value of pre-treatment with a P2Y 12 receptor, they indirectly support the concept that a high level of P2Y 12 receptor inhibition at the time of a PCI is associated with a reduction in ischaemic risk. How a strategy of cangrelor might compare with the administration of an oral P2Y 12 inhibitor immediately before the procedure (if not earlier) remains unknown, particularly (though not exclusively) if a fast acting and potent P2Y 12 inhibitor like prasugrel or ticagrelor (and even 600 mg of clopidogrel) were given before the PCI. One might speculate that the greatest benefit from this agent would be in ACS (STEMI, NSTEMI) patients. However, the benefit of cangrelor in CHAMPION-PHOENIX was similar in ACS and non-ACS patients (P int ¼ 0.98). Of note, there was a very short or even absent overlap in the treatment transition from cangrelor to clopidogrel in the cangrelor arm of the trials. Considering the delayed onset of the antiplatelet action of clopidogrel and a competition for binding of two drugs at the receptor level, 45 this may have at least in part contributed to the performance of the experimental study arms in the CHAMPION trials. Cangrelor (Kengrexal, the Medicines Company) was approved by the US Food and Drug Administration (FDA) on 22 June 2015 for reducing thrombotic events in patients undergoing PCI. European Medicines Agency approval for the drug was granted in March 2015; the average wholesale price is 350 Euros per vial in Europe and $750 per vial in the USA, although the actual prices may vary somewhat from country to country. Based on the average wholesale price of cangrelor ( US $750 per vial), the cost of administering cangrelor for any PCI procedure that takes 2 h or less (based on the recommended duration of infusion of 2 h, or the duration of a PCI, whichever is longer) would be US$750.00 (for one vial) if the patient weighed less than 100 kg, and US$1500 (for two vials) for patients weighing 100 kg or more.
Additional trials specifically designed to evaluate pre-treatment with cangrelor are needed. Such studies might be most useful to clinicians if they compared the administration of cangrelor in the P2Y 12 pre-treatment in ACS cath lab with a rapidly acting and potent agent like ticagrelor (administered upstream or in the cath lab) or prasugrel (administered in the cath lab). A practical benefit of cangrelor that all other P2Y 12 inhibitors lack is its fast offset of action if CABG surgery is needed, or when an initial diagnosis of an ACS is mistaken and the patient requires urgent surgery, i.e. for an aortic dissection. Moreover, cangrelor might be the ideal agent for P2Y 12 inhibition in haemodynamically unstable or intubated patients who are unable to swallow, or who might not fully absorb an oral antiplatelet agent due to cardiogenic shock. In such a scenario it would also have as a benefit the ability to provide definite and rapid effects, thereby avoiding the impaired and unreliable absorption of drugs from the gastrointestinal tract. Finally, with its immediate onset of action, it might offer an ideal alternative to upstream treatment with the other oral P2Y 12 inhibitors. 46 Indeed, it might be a good strategy to use cangrelor in high-risk patients who were not adequately pre-treated with an oral agent, beginning in the cath lab. Then, one should administer an oral agent as soon as possible-for ticagrelor that can be during the cangrelor infusion. For clopidogrel and prasugrel, it must be minutes after the cangrelor infusion has ended (or even 30 min before cangrelor is stopped for prasugrel). 47 Cangrelor blocks the binding of clopidogrel and prasugrel to P2Y12 receptors 45 ; it does not block ticagrelor binding.
Current guidelines
As the studies above reveal, the data in support of pre-treatment with a P2Y 12 inhibitor might best be described as suggestive, indirect, and weak. This is generally reflected in the current guidelines for both Europe and the USA. inhibitors should be given as early as possible or at the time of primary PCI (class I LOE B). With the use of the word 'or', the guidelines do not indicate whether 'as early as possible' is preferable to 'at the time of primary PCI'. Since there are no data indicating that pretreatment in STEMI is better or worse, we understand the lack of clear guidance as worded. The AHA/ACC 2014 NSTEMI guidelines 5 recommend the administration of P2Y 12 inhibitors 'before the PCI procedure' without explicitly commenting on when that should be.
Conclusions
The issue of pre-treatment with P2Y 12 receptor inhibitors in ACS patients remains an area of ongoing debate; many unanswered questions remain. It must be emphasized here that all dedicated randomized trials on this subject were negative for the primary endpoint. There are no randomized data supporting routine pre-treatment of ACS patients with a P2Y12 inhibitor, whether they are initiated in the pre-hospital setting, emergency department, or anywhere. Table 5 summarizes the authors' 'pieces of advice' on pre-treatment in NSTEMI and STEMI patients. For clopidogrel, data regarding pre-treatment dates back to studies conducted a decade ago.
11,12,32 -34 Large dedicated trials in the contemporary era have not been performed, and are unlikely to be performed. Randomized data from adequately powered, contemporary large-scale trials are now available for prasugrel and ticagrelor. 7, 17 However, the trials evaluating pre-treatment with those potent drugs did not meet their primary endpoint, and failed to provide strong evidence for a pre-treatment approach. While pretreatment remains biologically appealing and intuitive, particularly for ACS patients, the rapid onset of action of both ticagrelor and prasugrel raise questions about the risk/benefit ratio for pretreatment. If pre-treatment is administered with these drugs, the higher bleeding rate seen in some pre-treatment studies can be minimized by using a radial rather than femoral artery access approach. Currently, decisions about pre-treatment appear to be guided by clinician's assessment of individual patient's risk for thrombosis and bleeding. The shorter the duration of time between pre-treatment and PCI, and the slower acting and less potent the P2Y 12 inhibitor administered is, the less likelihood there is that benefit will be achieved from pre-treatment. And if a short duration of pre-treatment is pursued with the in lab administration of a P2Y 12 inhibitor, the greater the chance of benefit if the P2Y 12 inhibitor administered is a rapidly acting, potent agent than if a slower and less potent agent is administered. Table 5 Suggestions on pre-treatment in non-STE elevation myocardial infarction and STEMI patients NSTEMI It is advisable to administer a potent and rapidly acting antiplatelet agent (prasugrel or ticagrelor) once the coronary anatomy is known and the patient proceeds to immediate PCI Ticagrelor has been evaluated in ACS patients as a strategy including pre-treatment. But whether ticagrelor is more or less effective and safe in these patients if it is first given in the catheterization laboratory is not known If prasugrel or ticagrelor are contraindicated and clopidogrel is the remaining option for oral antiplatelet treatment, pre-treatment before coronary angiography may be advisable for patients with low bleeding risk and a high likelihood for immediate PCI, especially if radial access is planned
STEMI
Routine pre-hospital pre-treatment cannot be recommended for patients with STEMI over the in-lab administration of the drug since the two strategies had similar outcomes. Especially in cases of uncertainty for the diagnosis and whenever surgical aetiologies have not been excluded pre-hospital pre-treatment cannot be recommended It can be advisable to administer potent and rapidly acting antiplatelet agents (prasugrel or ticagrelor) in the emergency department (in-hospital) once the diagnosis of STEMI is confirmed and the patient proceeds to primary PCI If prasugrel or ticagrelor are contraindicated, it may be advisable to administer clopidogrel upstream as soon as a diagnosis of STEMI is confirmed and primary PCI is planned
The table summarizes pieces of advice for pre-treatment with the oral P2Y 12 receptor inhibitors. PCI, percutaneous coronary intervention.
